Prof. Masao Omata was the Chairman of the Department of Gastroenterology at the University of Tokyo, Japan. He graduated from the Chiba University School of Medicine and continued his training at Yale University, USA and in the Liver Unit at the University of Southern California. In 1992, he became Chairman of the Second Department of Internal Medicine at the University of Tokyo, Japan and then subsequently became Chairman of the Department of Gastroenterology. Under his leadership, the Department of Gastroenterology had become one of the foremost centers in its field.
In 2009, he was promoted to become the president of two hospitals: Yamanashi Central and Kita Hospitals to upgrade the medical care system in Yamanashi Prefecture, west of Tokyo, where, although scenic place with Mt. Fuji, hepatitis virus infection is endemic. The governor of Yamanashi has asked Prof. Omata to combat with the liver diseases of his homeland under his expertise and also run the two hospitals as a president.
Prof. Omata has made numerous seminal contributions to the fields of gastroenterology, hepatology, HBV and HCV, including the first description of the association between pre-core HBV mutants and fulminant hepatitis (N Engl J Med 1991), and the extremely high eradication rate of acute HCV by interferon (Lancet 1991). In addition, his group was the first to document the presence of cccDNA of HBV in human samples as a key marker of antiviral resistance (Hepatology 1985). Other major contributions include the emphasis of a viral etiology for hepatocellular carcinoma in 1970s in the USA (Gastroenterology 1979), as well as the first description of ‘fibrolamellar carcinoma’ (Cancer 1980).
He also demonstrated that the eradication of HCC decreased the incidence to one-fifth of the untreated, and fibrosis regression rate was 0.28 Fibrosis Stages/year. He also has established the largest volume center of HCC treatment by educating more than 200 young hepatologists and gastroenterologists at the University of Tokyo.
He has published over 950 articles in peer-reviewed English journals (5 N Engl J Med, 6 Lancet, 40 Gastroenterology, 53 Hepatology) in all disciplines of gastroenterology and hepatology (total impact factors: 4145, total citations: 20375 times).
He was the Presidents of the 17th Asian Pacific Association for the Study of the Liver (APASL) in 2007 and the 50th Japanese Society of Gastroenterology meeting in 2008. Currently, he is in charge of APASL-Tokyo-Secretariat.
HBV; HCV; HCC
Prof. Shu-Kui Qin, President of Chinese Society of Clinical Oncology (CSCO) and Vice-President of Nanjing Bayi Hospital and Director of PLA Cancer Center, is a senior medical oncologist, especially focusing on the Gastro-intestinal cancer and Liver cancer.
Prof.Qin holds some important positions in a variety of international and domestic academic organizations, including Council Member of Asia Clinical Oncology Society (ACOS), Senior Council Member of Chinese Anti-Cancer Association (CACA), Vice- President of the National Committee for Cancer Palliative Therapy & Pain Control, Chair of Liver Cancer group of National Ministry of Health, etc. He acts as the Editor-in- Chief of “Journal of Chinese Clinical Oncology” and “The Oncologist (Chinese version) ” , the Associate Editor-in-Chief of “Chinese Clinical Oncology Year-Books”, “Journal of Cancer Research and Clinical” and “The Chinese-German Journal of Clinical Oncology” etc.
Up to now, Prof. Qin has published more than 400 medical papers and 45 academic works, has participated in more than 82 international multi-centers clinical trials and 51 domestic clinical trials. Prof. Qin’s outstanding contributions to both academic and research fields were highly rewarded including Special Talent Allowance of State Council and more than 16 Chinese National and Province scientific awards.
Gastro-intestinal cancer; liver cancer
Dr. Buell is the Director of the Tulane Transplant Institute and Director of Transplantation at the New Orleans Children’s Hospital, the Louisiana State University. Currently, Dr. Buell is a tenured Professor of Surgery and Pediatrics at Tulane University and the Louisiana State University. Dr. Buell has clinical interests in drug and medical device development including clinical immunology and stem cell technology. His medical interests are in health care disparity, medical economics, health policy, and systems development. Dr. Buell’s expertise is in liver and bile duct cancer, as well as solid organ and composite tissue transplantation.
Dr. Buell received his undergraduate from Fordham University in New York City and subsequently earned his medical degree from the University of Rochester, and a Mater’s of Business Administration from Tulane University. Dr. Buell completed his general surgery residency at the University of Maryland and Shock Trauma Center. Dr. Buell subsequently completed two fellowships, the first in surgical oncology at the National Cancer Center, National Institutes of Health and the second his multi-organ transplant fellowship at the University of Chicago. Dr. Buell has received numerous awards and fellowships including The Dr. Leak award from the American Cancer Society. Dr. Buell was trained as a basic scientist at the National Cancer Institute, National Institutes of Health and completed his post-doctoral research in the molecular mechanisms of DNA platination and the implications of hyperthermia and tumor necrosis factor in the modification of snip gene transcription.
Subsequently, Dr. Buell pioneered the field of laparoscopic liver surgery has become a thought leader in device development, clinical trials and translational research. Since his arrival in New Orleans he has re-organized and realigned the Tulane and Louisiana State University programs to provide comprehensive transplant and liver tumor care for adults and children in the greater Louisiana region. In this region with significant financial and racial disparity, Dr. Buell and his collaborator Dr. Friedlander have worked with the ministers of the Ninth Ward to address systemic and regional racial disparity to provide improved healthcare to the most financially disparite.
Transplantation & Hepatobiliary
4. Minimally invasive liver surgery
Guangwen Cao is the chairman of the Department of Epidemiology, Second Military Medical University (Shanghai, China). He was graduated from Second Military Medical University as PhD and MD student and received medical trainings in Baylor College of Medicine and University of Texas MD Anderson Cancer Center (Houston, USA). Prof. Cao serves as the principal scientist of the National Key Basic Research Program (973 program) in cancer research and the Distinguished Young Scholar in China. Prof. Cao has published 120 research papers in international journals.
Biomarkers and genetic disposition on carcinogenesis and metastasis of hepatocellular carcinoma; renal cell carcinoma; lung cancer; gastric cancer; colorectal carcinoma; infectious cause of hepatocellular carcinoma; interaction between hepatitis B virus and genetic predisposition on hepatocarcinogenesis; quick pathogen identification and epidemiological outbreak study of emerging infectious diseases of natural sources and manmade; disaster medicine
Professor Jia Fan, the director of Zhongshan Hospital, Fudan University, executive deputy director of Liver Cancer Institute of Zhongshan Hospital, Fudan University, deputy director of Fudan University Liver Surgery department, vice director of Shanghai liver tumor clinical center, fellow of American College of Surgeons, presided over 18 national and provincial major research projects and published more than 550 papers (more than 110 papers in the SCI journals). He has won a lot of awards and honorary titles, Second Prize of National Science and Technology Progress Award in 2012 and 2012, etc.
1. Liver transplantation
2. Surgical treatment for liver tumors
Professor Jinlin Hou, the director of Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, chairman of Asian Pacific Association for the Study of the Liver (APASL), chairman of Infection branch of Chinese Medical Association, vice director of Guangdong Provincial Infectious Diseases Committee, director of Infectious Diseases and Parasitology Committee, was named as Zhujiang Scholar and selected for national “New Century Talents Projectals”. He has hosted five national projects, such as National Outstanding Youth Fund, Key Project of National Natural Science Fund, and National 973 sub-project, ect.
Prof. Farinati Fabio graduated in medicine and surgery with full marks and laude Padua University, Italy in 1978. then received his MD specialization in gastroenterology with full marks and Laude, Padua University in 1982, and PhD specialization in oncology, Padua University in 1987. Now he is the full professor of gastroenterology, department of surgical and gastroenterological sciences, Padua University. He has more than 280 publications in PubMed with an IF > 1,000 in highly ranked international scientific journals, 55 full papers in Italian journals, has written 42 book chapters.
GI cancerogenesis and clnical practice, with specific interest in gastric and liver cancer, precancerous conditions and lesions in esophagus and stomach.
•Responsible for grants by the Italian Ministry of Health and University and other private and public organization.
•Coordinator of the GENE group (Hepatocarcinoma Group North East Italy)
•Coordinator of the Section of Oncology of the Italian Society of Gastroenterology
•Vice President of the Italian Society of Gastroenterology
Mark Feitelson attended Cypress College (Cypress, CA) from 1970-72, and then received a BS degree in Biology from the University of California, Irvine in 1974. Advanced studies resulted in a PhD in Microbiology and Immunology from the UCLA School of Medicine in 1979. His thesis presented the genetic organization of the rabbit papilloma virus. He was then an American Cancer Society Postdoctoral fellow in the Department of Medicine at Stanford University from 1980-1982, where he started his work with hepatitis B virus (HBV). He was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (who won the Nobel Prize for his discovery of HBV) where he continued his work in HBV. He is presently Professor of Biology at Temple University and Associate Director of the Temple Biotechnology Center. He has been consistently funded by NIH and foundations since 1988 for basic science work on HBV and has attracted 10 contracts from industry for translational and applied work since 1997. He has over 100 publications in highly ranked international scientific journals, has written two books; delivered more than 160 oral presentations and/or posters at national and international scientific meetings, and has delivered more than 100 invited lectureships all over the world.
Molecular pathogenesis of hepatitis B and C viruses in liver cancer; hepatitis B
Liver cancer and liver transplantation; tumor infiltration; metastasis and extended resection in liver; gallbladder and pancreas; as well as promotion of surgical technology innovation by combining medical science and engineering
Go Wakabayashi, earned his degrees from Keio University School of Medicine, Tokyo Japan. He was trained at Department of Surgery at Massachusetts General Hospital and Harvard Medical School. After working as an assistant professor at Department of Surgery, Keio University School of Medicine, he was recruited as professor and chairman of Department of surgery at Iwate Medical University School of Medicine in 2005. His expertise includes Hepato-pancreatic Biliary Surgery, liver transplantation, and laparoscopic surgery. He has operated more than 150 cases of living liver transplantation and over 3000 cases of HPB surgery and laparoscopic surgery. He was awarded Gold Medal of Video Olympics at The World Congress of Endoscopic Surgery 1996. He also practices conventional HPB surgery and aggressive surgery as well. He holds numerous important positions in Japanese and international surgical societies.
Hepato-pancreatic biliary surgery; liver transplantation; laparoscopic surgery; conventional HPB surgery and aggressive surgery
Toxicology; nanotechnology and food safety
Prof. Giulio Belli obtained his MD degree from University of Naples in 1975. He is the Head of General and HPB Surgery, Loreto Nuovo Hospital, Naples, Italy since 2000. He is Founder member of the World Association of HepatoBilairyPancreatic Association (WHBPA), Former member of the Scientific Committee of International HepatoPancreatoBiliary Association (IHPBA), Former Member of the Council of the European Hepato-Pancreato-Biliary Association (EHPBA), Founder and Member of the Council of International HepatoPancreatoBiliary Association-Italian Chapter (IT-IHPBA), etc. He serves as Editorial Board Member and Reviewer for many famous journals. Also he is author of 11 HPB book chapters, Invited Speaker in 105 National and 61 International Congress, and author of 351 pubblications.
General and vascular surgery
Kenneth Siu-HoChok a specialist in general surgery based in Hong Kong, where he is Clinical Associate Professor in the Department of Surgery, the University of Hong Kong; Honorary Consultant in the Departments of Surgery at Queen Mary and Tung Wah Hospitals; Deputy Director of the Liver Transplant Centre and Director of High Dependency Unit (Surgery) at Queen Mary Hospital.
Dr Chok received his MBBS from the University of Hong Kong. In 2007, he attained his fellowship with the Hong Kong Academy of Medicine (Surgery) and became Deputy Chief of Residents at Queen Mary Hospital’sDepartment of Surgery, shortly progressing to Associate Consultant in 2008 and Consultant in 2011 at the age of 35. Dr Chok received his Master of Surgery from the University of Hong Kong in 2015 and became a fellow of the American College of Surgeons (ACS) in 2016 after having received the Carlos Pellegrini Traveling Fellowship award of the ACS. He is a famous Endoscopic-Laparoscopic HBP and Liver Transplant Surgeon in the territory.
Dr Chok has so far published 150 articles in leading peer-review journals on liver surgery and hepatocellular carcinoma, including Journal of Gastrointestinal Surgery, Surgery, World Journal of Surgery, Hepatology and Annals of Surgery. He is also a reviewer for many of these journals and frequently delivering lectures in various international meetings. Aside from hisoutstanding clinical and research duties, Dr Chok is actively involved in promoting organ donation in Hong Kong and is currently the Honorary Treasurer for the Hong Kong Society of Transplantation.
1. Extensive experience in managing all areas of complicated hepatobiliary, pancreatic diseases, deceased donor and living donor liver transplantation (including most technically demanding major vascular resection in HBP surgery, in-situ splitting and sequential liver transplantations)
2. Extensive experience in managing complex surgical problems in conjunction with other procedures (e.g. colectomy with synchronous liver resection)
3. Extensive experience in supervising different levels of surgeons
Dr. Lynn Feun is a medical oncologist in Miami, Florida and is affiliated with multiple hospitals in the area, including Jackson Memorial Hospital and Miami Veterans Affairs Healthcare System. He received his medical degree from Wayne State University School of Medicine and has been in practice for more than 20 years. Dr. Feun accepts several types of health insurance, listed below. He is one of 21 doctors at Jackson Memorial Hospital and one of 14 at Miami Veterans Affairs Healthcare System who specialize in Medical Oncology.
1. Developmental therapeutics
Dr. Geller is the Richard L. Simmons Professor of Surgery at the University of Pittsburgh School of Medicine, and Director of the UPMC Liver Cancer Center. As a hepatobiliary Surgical Oncologist, his clinical interests center on the evaluation and management of patients with liver cancers.
He has pioneered laparoscopic liver resection surgery. Dr. Geller and his team have performed more than 800 of these cases. Most of these patients are discharged home on the second post-operative day with 4-5 bandaid-sized incisions. He also specializes in performing laparoscopic radiofrequency ablations of liver tumors.
Dr. Geller is a member of many professional and scientific societies including the Society of Surgical Oncology, Society of University Surgeons, and the American Society of Transplant Surgeons.
Dr. Geller has published 280 scientific papers and chapters. He is often a guest lecturer speaking on the management of liver tumors and has presented at more than 360 meetings or seminars. He has active research grants from the NIH, and is also the Principal Investigator on Industry-sponsored clinical trials for liver cancer.
Prof. Jun Cheng, MD, PhD, is the vice president of Beijing Ditan Hospital, Capital Medical University. Dr. Cheng got his MD in 1986 from First Military Medical University (now Nanfang Medical University), and PhD in 1994 from Beijing Medical University (now Peking University Health Science Center). From 1994 to 1997, Dr. Cheng finished his postdoctoral training in the Department of Infectious Diseases, University of Texas Health Science Center at San Antonio, Texas, USA. Now Dr. Cheng is the Council Member, International Society of Infectious Diseases (ISID); the president of Asia-Pacific Alliance of Liver Diseases (APALD), Beijing; Advisory Board Member, National Committee of Diseases Prevention and Control, Ministry of Health and Family Planning; the president of Chinese Society of Tropical Diseases and Parasitology, Chinese Medical Association; vice president, Society of Infectious Diseases Doctors, Chinese Association of Medical Doctors; editor-in-chief, Infection International; editor-in-chief, Chinese Journal of Experimental and Clinical Infectious Diseases; editor-in-chief, Chinese Journal of Liver Diseases; editor-in-chief, Infection International, editorial board member of International Journal Infectious Diseases, editorial board member of Hepatology International.
Dr. Cheng has been engaged in the field of infectious diseases for longer than 29 years. His special interests include clinical treatment of viral hepatitis and basic research on virus-hepatocyte interactions. Dr. Cheng has 148 peer-reviewed papers published.
1. Clinical treatment of viral hepatitis
2. Basic research on virus-hepatocyte interactions
Hiroshi Yoshida, M.D. is graduated from Nippon Medical School (Bsc) obtained MD and subsequently entered the Department of Surgery in 1986. From 1988 to 1992, He attended Postgraduate course in Department of Surgery, Nippon Medical School and obtained PhD. In 1992, He was appointed clinical fellow of the Department of Surgery, Nippon Medical School. In 2003, He was appointed assistant professor and, in 2005, associated professor of the Department of Surgery, Nippon Medical School. In 2010, He was appointed associated professor of the Department of Surgery, Nippon Medical School Tama Nagayama Hospital. In 2011, he was appointed Chief and Clinical Professor of the Department of Surgery, Nippon Medical School Tama Nagayama Hospital. In 2014, he was appointed Assistant Director of the Nippon Medical School Tama Nagayama Hospital.
1. Hepato-biliary-pancreatic surgery
2. portal hypertension; transplantation
3. interventional radiology
4. endoscopic treatment
Prof. Lu is the Director of Microbiology Department, Deputy Dean of Basic Medical Sciences，Peking University. Prof. Lu received his Ph.D. degree from Harbin Medical University in 1992 and completed his postdoctoral training in the Public Health School of Beijing Medical University in 1994. Then he worked as a research associated professor in the Research Center at the Third Affiliated Hospital of Beijing Medical University from 1994 to 1997. After that, he worked as a visiting scientist in the Department of Bioscience at Karolinska Institute, Sweden. Prior to return to China in 2005 to assume a professor at Peking University Health Science Center, he was a research scientist at the Children’s Hospital of Philadelphia and the Abramson Family Cancer Center, University of Pennsylvania. In 2012, he was promoted to be the director of the Department of Microbiology, and the vice dean of the School of Basic Medical Sciences.
Prof. Lu’s research has been focused on the Hepatitis B virus and its relevant human diseases. So far, he has authored more than 90 research articles in peer-reviewed journals including New England Journal of Medicine, Journal of Hepatology, and Cancer Research which have been cited over 2300 times. He is serving as editorial board members of several academic journals. Prof. Lu became a chief scientist of the National Major Scientific Project on Infectious Disease in China in 2008 and has been awarded twice the second prize of National Science and Technology Award.
Hepatopathy & Translational Medicine
1. Hepatitis B virus
2. Liver cancer
3. Liver fibrosis and cirrhosis
Jian-Guo Chen is a Professor, Chief of Department of Epidemiology, Vice Director of Nantong Cancer Institute, Nantong Tumor Hospital of Nantong University; and Research Fellow and Chief of Qidong Cancer Registry, Former Vice Director of Qidong Liver Cancer Institute.
He was graduated from Nantong Medical College, and Shanghai Medical University. He once majored in Medical Statistics at National Teachers Class of Health Statistics in Shanxi Medical College; Majored in Cancer Epidemiology at International Agency for Research on Cancer (IARC); and Majored in Epidemiology at Johns Hopkins School of Public Health (JHSPH). He was a Visiting Scientist at IARC in early 2000’s. He is an Awardee of “Young and Middle-Aged Expert with Outstanding Contribution of Jiangsu Province”, and Awardee of "the Development and Contribution of Public Health and Preventive Medicine" awarded by China Preventive Medicine Association, and also, an Expert receiving Special Government Allowances of State Council of China. Dr Chen was a Vice Chairman of “Committee of Cancer Registration and Monitoring, Health Information Association of China”, Committeeman of “Liver Cancer Society, Chinese Anti-Cancer Association”; He is now a Vice Chief of “Expert Team of Early-Diagnosis & Treatment for Liver Cancer, Ministry of Health of China”; Committeeman of “China Medicinal Biotech Association Biobank Branch”; Adviser of “Jiangsu Liver Cancer Society ”, Vice President of “Nantong Anti-Cancer Association”, and Chairman of “Nantong Tumor Epidemiology Society”. He has been engaging in cancer research, such as (liver) cancer epidemiology, cancer etiology, cancer prevention, for many years, with related research projects from home and abroad. He had received several Science and Technology Progress Awards from the Ministry, Province, and China Medical Association in the past. As first author or corresponding author he has published more than 170 articles in Chinese or in English, and some co-edited books.
Antonio Giorgio was graduated in Federico II University Naples, Italy. Founder and Director of Interventional Ultrasound Unit D. Cotugno” Hospital - Naples, Italy. His clinical and research activity is mainly focused on the ultrasound of liver diseases and ultrasound guided percutaneous treatment of HCC on cirrhosis, hydatid, abdominal abscesses and metastatic tumors of the liver and, more recently, intrahepatic cholangiocarcinoma.
He is author of more than 350 scientific publications.
He is author of many chapters in texts prepared by other authors, in general about ultrasound diagnostics (some of these are: Italian Treaty on Ultrasound - 2000, Atlas of Abdominal Ultrasound – 2003, Ultrasound in Internal Medicine - 2008).
1. Ultrasound diagnostics in liver diseases and the ultrasound guided percutaneous treatment of HCC on cirrhosis
2. Hydatid and simple liver cysts
3. Abdominal abscesses and metastatic tumors of the liver and, more recently
4. Intrahepatic cholangiocarcinoma
In 2014, Dr. Hu has been selected as Changjiang Scholar Distinguished Professor by the Chinese Ministry of Education. Dr. Hu’s long-term research interest mainly lies in the molecular epidemiology and the genetic basis of various complex diseases. To date, he has published over 200 scientific studies in the past years. Most of these papers were published in the internationally recognized journals, such as Nature Genetics, J Clin Oncol., J Clin Invest., Am J Respir Crit Care Med., Hepatology and Nature Communications etc. Up to now (2017), these papers have been totally cited nearly 10000 times according to the ISI Web of Knowledge.
1. Molecular Epidemiology of complex diseases
2. Reproductive Medicine
3. Molecular Genetics of Cancer
Dr. Ding is deputy director of China Research Hospital Society of Hepatology, vice chairman of Chinese research hospital of liver disease committee, an academic leader of Beijing High-level health personnel of Gastroenterology, and a candidate of Talents Project of Beijing municipal New Century Millions.
He is also a committee of the Beijing Medical Society of Hepatology and Digestive Endoscopy, a committee of the liver fibrosis and cirrhosis study groups of Chinese Medical Society of Hepatology and Digestive Diseases, a supervision committee of China Sports Science Society of Sports Medicine and an editorial board member of the Journal of Chinese Hepatology, Capital Medical Science, China Medical University, Degestive Disease and Clinical Hepatology. member and secretary of Beijing Medical Association of Liver Disease, Digestive Endoscopy.
1. Clinical study from chronic liver diseases development hepatocellular carcinoma (HCC) cohort
2. Complications of liver cirrhosis with portal hypertension
3. Early diagnosis and Biomarkers research of HCC
4. Pathophysiology and Cell Biology of portal hypertension and liver cancer with cirrhosis
5. Pathogenesis and therapeutic study of experimental portal hypertension and HCC
6. Techniques involved include preparation of cirrhosis models induced by human serum albumin or carbon tetrachloride, biochemical determination of NO, NOS, H2S
7. GI Endoscopy in liver diseases and HIV/AIDS
Dr. Lei Chen received his bachelor degree from Fudan University, followed by a Ph.D degree from eastern hepatobilliary surgery institute/hospital (EHBI/EHBH) in Second Military Medical University (SMMU), Shanghai, China, under the supervision of Professor Hongyang Wang (email@example.com), with an emphasis on cancer signal transduction. In the past few years, I have led projects focusing on the molecular mechanism of hepatocellular carcinoma (HCC) development and progression, especially on the roles of inflammation-related hepatocytes apoptosis, liver injury and also the function of non-coding RNA. The major discoveries from our group include:
(1) The Screening and Identification of Key molecular for HCC classification and Prevention, including non-coding RNA (including mir-484,mir-429, et al);
(2) The activation of TLR4/MyD88 signaling in liver parenchymal cells plays a pivotal role during the early progression of HFD-induced NAFLD via secreted HMGB1 stimulation, which in turn may lead to liver injury and induce cirrhosis;
(3) The functional role and underlying mechanism of EGFR-related genes involving drug resistance of targeting EGFR therapy.
(4) a set of promising circulating miRNAs were identified as the predictive biomarkers for HCC with a large cohort, which can monitoring the occurrence of HCC in advancing traditional methods (AFP detection and ultrasound imaging.
Till now, Dr. Lei Chen have published over 50 papers in several journals, including Gastroenterology（2）, Gut（2）, Nature Communications（1）, Hepatology（2）, Cancer Research（1）, Journal of Hepatology（3）, Journal of Virology, Molecular Cancer, FEBS Journal, Nature Cell Biology，J.E.M, J.B.C，total citations are over 1500，H-index is 20. The number of first author or correspondence author paper is 24, ten of which were published in Journals with impact factor over 10.
Cell signaling transduction
Cancer stem cell
Laboratory of Genomic Diversity, National Cancer Institute at Frederick, National Insitutu of Health, Frederick, MD USA 11/2006 - 10/2008
Project: Screening candidate genotypes for hepatocellular carcinoma in an oxidative-stressed population.
Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University in the City of New York, New York City, NY USA 9/2005 - 10/2006
Project: Aflatoxin B1 and hepatitis B virus relevant oxidative-stress in inducing hepatocellular carcinoma in a Chinese population.
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China 10/2003 - 9/2005
Project: Screening candidate genotypes for hepatocellular carcinoma in an oxidative-stressed population-model exposed to aflatoxin B1.
Department of General Surgery, The West China Hospital, West China University of Medical Science, Chengdu City, Sichuan Province, China. 09/2000 - 06/2003
Project 1: The Association between Oxidative DNA Damage-Base Excision Repair Mechanism and Hepatocarcinogenesis in High-risk Areas for Hepatocellular Carcinoma in Guangxi China.
Project 2: The implementation of clinical liver transplantation.
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China 09/1994 - 06/1997
Project: The colonial origins of recurrent Hepatocellular Carcinomas after radical resection.
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China
Residency 07/1993 - 06/1999
Attending Surgeon 07/1999 - 12/2003
Associate Professor 01/2004 - 11/2006
Professor, Deputy Director 12/2006 - 01/2014
Professor, Head 01/2014 - present
• As the head of Department of Hepatobiliary Surgery, in charge of the daily clinical work of diagnosis and treatment in ward.
• Responsible for the instruction of clinical practice of graduate students and training surgeons.
• In charge of clinical and research work in liver transplantation group in the First Affiliated Hospital of Guangxi Medical University.
• In charge of research work on molecular oncology, mainly in the field of primary liver cancer.
• Identification and characterization of cancer related genes and micro-RNAs in hepatocellular, esophageal and nasopharyngeal carcinomas;
• Molecular characterization of tumor microenvironment, especially cancer fibroblasts secreted proteins.
1. Experimental hepatology and drug targeting
2. Biomedical investigation in liver and gastrointestinal diseases
Dr. Kwee is director for PET Research of the Queen's Medical Center and an associate professor of John A. Burns School of Medicine, University of Hawaii at Manoa. He is the principal investigator of NCI funded clinical trials (NCT00928252 and NCT00928174) evaluating an investigational positron tomography (PET) diagnostic for liver and prostate cancers. Recent work has also involved the analysis of free circulating nucleic acids as a complement to imaging biomarkers, PET-guided radiation therapy planning, and using PET imaging as a means to annotate tissue gene expression profiling. Another research-relevant interest is biomedical ethics.
Positron tomography; Imaging biomarkers; Radiation therapy; Cancer diagnostic
Dr. Kim is Professor of Radiology and Medicine (Medical Oncology), Vice Chair of Clinical Research and Chief of Interventional Radiology at Yale School of Medicine. He also leads the Smilow Interventional Oncology program. Dr. Kim was trained at the MD Anderson Cancer Center and the Johns Hopkins Hospital. He is an authority in image-guided interventional oncology and advanced cancers. He is an expert in minimally invasive treatments and takes care of patients with advanced cancers with the most advanced anti-cancer treatments such as targeted drug delivery and targeted radiation delivery therapies to liver cancers (TACE, Y90 radioembolization), image-guided precision microwave ablation, radiofrequency ablation and immuno-cryotherapy. Dr. Kim’s research focus is targeted therapy with immune modulation in advanced cancers. Dr. Kim is a member of Yale Comprehensive Cancer Center, New Haven, CT.
His research interests and publications have centered on investigating novel image-guided therapies in Interventional Oncology, specifically in image-guided ablations including high intensity focused ultrasound surgery, targeted drug/radiation therapies for cancers, immune-modulation and biomarkers.
Senior Clinical Researcher in Hepatology and Associate Professor of Gastroenterology at the University of Bologna, Italy.
M.D. and Board Certified Gastroenterologist.
Over 20 years-experience and expertise in clinical research programs, patient management and care in the diagnosis and treatment of hepatitis C (HCV) and hepatitis B (HBV).
Author of seminal works leading to the knowledge and adoption of ribavirin in the treatment of chronic hepatitis C. First ever use of interferon-alfa plus ribavirin combination therapy as standard treatment for chronic hepatitis C (published in Gastroenterology, 1994).
Leading expert in the management of liver cirrhosis, hepatocellular carcinoma, in the selection and evaluation of candidates for liver transplantation, and in the post-liver transplant patient management.
Active role in phase II and III clinical trials under ICH-GCP regulation, in the therapeutic area of viral hepatitis, including HCV protease and polymerase inhibitors (DAA).
Responsible of active research programs in chronic viral hepatitis at the University S. Orsola Hospital in Bologna.
Author of over 60 original scientific papers published in peer-reviewed medical or scientific journals as The Lancet, Gastroenterology, Hepatology, Journal of Hepatology, Journal of Medical Virology, Liver Transplantation.
Presenter of over 20 original scientific communications at AASLD Annual Liver Meeting, AGA/DDW Annual Meeting, EASL International Liver Conference.
Member of international scientific societies (AASLD, EASL, AISF) and official peer-reviewer for leading scientific journals (NEJM, Lancet, Gastroenterology, Hepatology, J Hepatol, PlosOne).
Member of the ruling Governing Board of the University of Bologna DIMEC Department and of the DIMEC Department Research Commission.
1. HCV infection and hepatocarcinogenesis
2. HBV infection and hepatocercinogenesis
3. Antiviral treatment and risk of hepatocellular carcinoma
4. Locoregional therapy of hepatocellular carcinoma
Tan To Cheung, MBBS, MS, FRCS(Ed), FCSHK, FHKAM, is the Chief of the Division of Hepatobiliary and Pancreatic Surgery within the Department of Surgery, Queen Mary Hospital, the University of Hong Kong, and a Council member of the Hong Kong Society of Hepatobiliary and Pancreatic Surgery. He is also Associate Professor of Surgery at the University of Hong Kong.
Dr. Cheung received his medical degree from the University of Hong Kong. After graduation, Dr. Cheung started his career as surgeon at Queen Mary Hospital. With his interest in complicated liver surgery and liver transplantation, he became a staff member of the Division of Hepatobiliary and Pancreatic Surgery in 2006.
Dr. Cheung is one of the leading experts in laparoscopic liver resection in Hong Kong. He has performed more than 300 pure laparoscopic liver hepatectomies in Hong Kong. He published the results of laparoscopic hepatectomies at Queen Mary Hospital in various journals, including Annals of Surgery and World Journal of Surgery.
He is keen on new procedure development and is an active researcher in the fields of liver transplant, complicated liver surgery, ALPPS, minimally invasive surgery for liver cancer, and the role of dual tracer PET CT in the diagnosis of HCC. Dr. Cheung has obtained his doctoral degree (Master of Surgery, HKU) with research on the treatment of HCC in liver cirrhosis. He is the world’s leading expert in the area of high intensity focused ultrasound (HIFU) therapy for HCC. He performed the first HIFU treatment as a bridging therapy for liver transplant in the world.
Dr. Cheung was a recipient of the GB Ong Travelling Fellowship Award. He has won many other awards including travelling awards, Best Oral Presentation awards, Best Video awards and Best Poster awards in various international meetings. He has authored more than 140 peer-reviewed articles and other publications, and is frequently invited to lecture internationally and to present in plenary sessions. He has mentored a large number of trainees.
liver transplant, complicated liver surgery, ALPPS, minimally invasive surgery
Dr. Zhang is the professor of department of epidemiology of Military Medical University of Navy. Prof. Zhang has research interests in the field of molecular epidemiology in prevention of hepatocellular carcinoma and prostate cancer. He received his undergraduate, MD and PhD from Harbin University and got medical trainings in Griffith university in Australia. He has received numerous awards from Shanghai municipal government and National Cancer Society. Prof. Zhang has published 60 research articles in international journals.
Molecular epidemiology in the study of biomarker and genetic predisposition on carcinogenesis of hepatocellular carcinoma and prostate cancer; the risk factors of environment and genetic in the development of these cancers
Dr. Jianli Geng is the vice president of Weihai Municipal hospital affiliated to Dalian Medical University, especially focusing on the Liver cancer.
Dr. Geng holds some important positions in a variety of domestic academic organizations, including Vice- President of Interventionalists of Shandong Anti-cancer Association and Council Member of pediatric surgery of Shandong Medical Association, etc.
Up to now, Dr. Geng has published nearly 10 medical papers and his outstanding contributions to both academic and research fields were highly rewarded including several Chinese National and Province scientific awards.
Extensive experience in the surgery of complicated hepatobiliary and pancreatic diseases, including liver tumor, hepatic hemangioma, perihilar cholangiocarcinoma and pancreatoduodenectomy, as well as promotion of surgical technology innovation by utilizing Radiofrequency Ablation and Biliary Stent.
Professor Hui-Chuan Sun is currently deputy head of the Department of Liver Surgery and Transplantation in Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China.
He graduated from the Shanghai Medical University (now the Fudan University Shanghai Medical School) with a bachelor of medicine degree in 1992, and Ph.D degree in 1999, and became professor of surgery in 2009.
Prof. Sun’s research interest is development of novel treatment for liver cancer, especially pre-operative assessment of liver function to ensure safety of hepatectomy, through non-invasive methods. He is also interested in and understanding of mechanism of tumor metastasis, especially the role of angiogenesis and macrophages.
Prof. Sun has published more than 50 papers in the peer-reviewed international journals.
Primary liver cancer
Novel treatment and mechanisms
Dr. Chunfeng Qu is the Director of Immunology Department, and the Principle Investigator of State Key Lab of Molecular Oncology at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing. She received her Clinical Medicine degree in 1985 from Weifang Medical College, Shandong Province. In 1990, she obtained the Master degree of Medical Virology and Immunology from Hubei Medical College (Wuhan University Medical College) and completed her PhD (major: Immunology) in 1999 at Peking Union Medical College in Beijing, China. From May of 2000 to September of 2005, she received her postdoctoral training at Mount Sinai School of Medicine in New York, USA, supervised by Dr. Gwendalyn J. Randolph and Dr. Xiu-Min Li. During this period, she received a Keystone Symposia Scholarship for “Dendritic cells: Interfaces with Immunobiology and Medicine” in March of 2003. From September of 2005 to December of 2007, she was employed as the Instructor of Immunology at the Mount Sinai School of Medicine in New York, USA. From January 2008 she took the position as the Professor of Immunology at the Cancer Hospital/Institute (National Cancer Center/Cancer Hospital), Chinese Academy of Medical Sciences & Peking Union Medical College.
Dr. Qu investigated how the human blood monocytes differentiated into antigen presenting dendritic cells in response to influenza A virus in peripheral tissues and the role of the monocyte-derived cells for antigen presentation. In Recent years, she with her team investigated the long-term effect of neonatal HBV vaccination, the status of immunological memory among the vaccinated young adults. They suggested the booster strategies administrated at adolescents to the individuals who were born to HBV-infected mothers after they have completed the series of HBV vaccination at infantile in order to keep the protective effect of neonatal HBV vaccination. They also investigated how to induce protective immune responses to HBV proteins in the individuals with chronic HBV infection.
Dr. Qu’s research aim is to control the liver cancer by using immunological approaches. She is also interested in identifying the effect of aflatoxin exposure on liver cancer since high espouse of aflatoxin served as the important co-factor for liver cancer development in the population with chronic HBV infection. She and her colleagues recently dissected the genomic features of the liver cancer associated with aflatoxin exposure. Their findings might be used to identify liver cancer patients due to aflatoxin exposure, and select therapies, such as PD therapy.
Cancer control by immunological approaches
1. Liver cancer
2. Colon cancer
Hong Tu, professor of oncology at Stated Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao-Tong University School of Medicine, is a medically trained researcher with graduate training in molecular virology at Shanghai Medical University and University of Southern California, and postgraduate training in cell biology at INSERM U370, Necker/Pasture institute, France. Dr. Tu has worked as a principal investigator in Shanghai Cancer Institute since 2007. Before, she was a research instructor in Penning Biomedical Research Institute, Louisiana State University, USA and a lecturer in Shanghai Medical University. Her research interests include 1. Etiology of HCC and ICC. 2. Biomarkers of primary liver cancer. 3. Systemic regulation of liver cancer by nervous, endocrine and immune systems. Being a principal investigator, Dr. Tu has completed several projects from National Natural Science of China projects, Chinese State Key Project Specialized for Infectious Diseases and Shanghai Municipal Science and Technology Commission. She has published more than 100 papers in peer-reviewed journals, and has been granted 4 patents related to the prediction and early diagnosis of HCC. Her research achievement was awarded the first prize of scientific and technological progress from the Ministry of Education. She is the editorial board of World Journal of Gastroenterology, and the Chinese journal Tumor. She serves as the referee of several national and international journals.
Primary liver cancer
2. HBV-related carcinogenesis
3. Systemic regulation
Dr. Biyun Qian is the Director of Clinical Research Center at School of Medicine, and the Associate Dean for Academic Affairs at School of Public Health, Shanghai Jiao Tong University. She is also the Vice President of Shanghai Tong Ren Hospital. She graduated from Tianjin Medical University, China and continued her training at Yale University, USA. Currently, Dr. Qian is a Professor of Epidemiology and Biostatistics at the School of Public Health, SJTU. Dr. Qian has interests in cancer molecular epidemiology and clinical research.
Dr. Qian was appointed as a faculty member in the departments of Epidemiology in Tianjin Medical University Cancer Institute and Hospital since receiving the master degree, rising to the rank of a full Professor. From 2011 to 2013 she served as a Program Director in Oncology at the National Natural Science Foundation of China. She joined the School of Public Health, SJTU in 2014. From then on, she also established the Clinical Research Center in the Shanghai Jiao Tong University School of Medicine. Dr. Qian is a senior member of the Committees on Epidemiology and Etiology of the China Anticancer Association. Moreover, she is also the senior members of Statistics and Health of Shanghai Medical Association.
Dr. Qian’s research focus on cancer epidemiology including surveillance, etiology, and molecular biomarkers and mechanisms. Her interests towards genetic susceptibility biomarkers and their interactions with environmental exposures, such as air pollution in cancer. Current research involved in post-GWAS and studying non-coding RNAs and the occurrence, development and prognosis of cancer.
She has successful completed over 30 research projects funded by the National Natural Science Foundation of China, the National 863 Project from the Ministry of Science and Technology of China, the American Cancer Society, and provincial and municipal governments. She has published more than 60 papers in peer-reviewed journals, She has won scientific research awards including a Chinese highest level award——National Science Progress Awards from Chinese government, and the Award of the National Natural Science Education Awards from the Ministry of Education in China, and others from the Municipal Science and Technology Progress Awards.
Cancer Molecular Epidemiology
1. Etiology and Chemoprevention: PM2.5 and cancer
2. Molecular biomarkers (non-coding RNA) and diagnosis, prognosis of cancer
3. Clinical research
Wen Wang is associate professor in the Department of Microbiology, Second Military Medical University (Shanghai, China). She got the PhD and MD degree from Second Military Medical University and as the visiting scholar in University of Washington (Seattle USA). In particular, her researches have been focused on exploring novel biomarkers, such as miRNA, expression profiles and regulatory networks in the progress of hepatocellular carcinoma (HCC).
HCV and HBV
AKAP and PKA pathway
Dr. Li is the department manager of Hepatic Surgery VI, AnTing district of the Eastern Hepatobiliary Surgery Hospital. Dr. Li is under the tutor of academician Wu Mengchao, Professor Cheng Shuqun, and is the expert of Shanghai science and Technology Committee, the member of IHPBA and A-PHPBA. Dr. Li has been engaged in Clinical and basic research on hepatitis-related HCC for a long time, diagnoses and treats more than 1000 patients and performs more than 200 operations each year. Dr. Li develops a series of surgical instruments associated with liver resection surgery. In the field of the basic research, Dr. Li promotes the possible mechanism of long chain noncoding RNA20951 affecting progression of hepatocellular carcinoma and demonstrates that ICAM1 can be used as one of the surface molecular markers of liver cancer stem cells.
Dr. Li is in charge of many scientific research subjects like The National Natural Science Fund, the sub-project of nation’s 973 Plans, and 10 subjects from Shanghai Education Commission, Shanghai science and Technology Commission, Shanghai health development planning commission. Dr. Li has published more than 30 papers, 19 papers of which is indexed by SCI, and the total impact factor is 60.14 points, the highest one is up to 18.37 points. Dr. Li has applied for and authorized 17 national patents and won the third prize of Shanghai science and Technology Progress Award.
Dr. Li has received numerous awards and fellowships including the “Shanghai Chenguang scholar” in 2007, the "5511" Talents of the Second Military Medical University in 2011, the “Shanghai Science and technology Youth star” in 2013, the “Outstanding young scholars” of the Second Military Medical University.
Hepatobiliary Surgery & surgical oncology
1. Liver Cancer
2. Portal Vein Tumor Thrombosis
3. Minimally invasive liver surgery
Deke Jiang, professor of Hepatology Unit, Nanfang Hospital, Southern Medical University (Guangzhou, China), who obtained his PhD degree of genetics at Fudan University (Shanghai, China), received training as post-doctor at the University of Chicago (USA), and acted as visiting scholar at Wake Forest University (USA). He has ever served as deputy team leader of the technology group of State Key Laboratory of Genetic Engineering, and assistant director of Genetic Epidemiology Research Center of Fudan University.
His research area is genetic mechanism and precision medicine of hepatitis B virus (HBV)-related diseases, such as chronic hepatitis B and liver cancer. He has focused on such studies for more than 10 years and published more than 60 outstanding peer-reviewed papers on high ranked international scientific journals, such as Nature Genetics, Hepatology, etc. All the papers have been cited for more than 800 times. One of his first-author papers that published on Nature Genetics has been cited for more than 110 times. This paper was voted as one of the "Top 10 Most Popular" domestic scientific research of 2012 by ScientificNet, and was widely reported by CCTV news and other medias.
He has been invited to report his research works in annual meetings of Asian Pacific Association for the Study of the Liver (APASL), American Association for the Study of Liver Diseases (AASLD) and American Society of Human Genetics (ASHG). He was awarded the Outstanding Scholar of Fudan University, Fusun Medicine Research Grant, and Roche Diagnostics China Medical and Life Science Education and Research Fund.
Human genetic epidemiology and pharmacogenomics research on chronic hepatitis B and hepatitis B virus-related hepatocellular carcinoma
Genomic translational research on cancer and other complex diseases
Zhao Jun, professor in Eastern Hepatobiliary Surgery Hospital, doctor of medicine, doctoral supervisor, professional technical level-7. He has long been engaged in hepatocellular carcinoma and liver transplantation. As the project leader, he has been responsible for the completion of the National natural science funds and Shanghai natural science funds; won first prize of Shanghai medical Science and Technology Award once, first prize of Shanghai Science and Technology Progress Award once, second prize of Shanghai medical science and technology once; engaged in the bookmaking of "The diagnosis and treatment of liver cancer". In recent years, he has published more than 20 papers as the first or the communication author, 10 SCI papers was included. At the same time, He act as the Committee member in general surgery department of the whole army, youth committee in organ transplant institute of Shanghai and committee member in colorectal diseases professional department of the whole army. He also acts as the deputy commitee of Shanghai preventive medicine association clinical prevention committee; the editorial board member of Hepatoma Research, the National 973 project backbone expert.
Diagnosis and treatment of primary hepatocellular carcinoma
Treatment of hepatic metastasis of colon cancer
Treatment of portal hypertension
Jun Li, MD & PhD is a professor and vice director in State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine. He is also a member of American Association for the Study of Liver Diseases (AASLD), the member of standing committee of Stem cells Translational Medicine in the Chinese Society for Anatomical Sciences (CSAS), the member of committee of Chinese Society of Tissue Engineering and Regenerative Medicine and the vice director of Youth Committee Member of Chinese Society of Hepatology.
Dr. Li’s primary areas of research involve the development of bioartificial liver support system for patient with severe hepatic failure. He spent three years working at the bioartificial liver laboratory at The First Affiliated Hospital, School of Medicine, Zhejiang University in China and received his Ph.D degree in 2003. Dr. Li also spent two and half years (2006.01-2008.04) as a postdoctoral fellow in Cedars-Sinai Medical Center in USA. His research focuses on the liver regenerative medicine with stem cell transplantation and tissue engineering technologies. Recently, Dr. Li firstly demonstrated that human bone marrow mesenchymal stem cell transplantation could prevent death from fulminant hepatic failure (FHF) in pigs and clarified its detailed mechanisms of stem cells transplantation. In recent years, Dr. Li has received 12 national key grants including the National Natural Science Foundation of China and “863 plan”. As a first or corresponding author, he wrote 20 papers published in peer-reviewed journals such as Gut and Hepatology etc. He is also an Editorial Board Member for Scientific Reports.
1. Stem cell transplantation
2. liver regeneration
Dr. Yao is a professor of Oncology and Director of Tumor Institute, Nantong University, Jiangsu Province, China. He graduated from Jiangsu University, got Master degree of Gastroenterology at Medical School of Nantong University, China, Ph.D. degree (1994) of Gastroenterology at Medical School of Tokushima University, Japan, and Post-doctor research at Molecular Medicine, Japan Society for the Promotion of Science (JSPS) from 2000 to 2002. He is members of International Liver Study, Europe, Asian, and Chinese Medical Association. He was guest professor of Jiangsu University from 1994 to 1998. Until now, he has guided more than 50 graduated students including Ph.D. or MD, Master, post-doctors, and visiting researchers. He has published a series of articles and wrote some books in Hepatology and Oncology. His research fields are early biomarkers of specific diagnosis and pathogenesis of malignant tumors.
Early diagnosis & Pathogenesis of HCC
Dr. Ma is the vice dean of School of Basic Medical Science, Shandong University. Currently, Dr. Ma is the professor of Dept. Immunology and Key Laboratory for Experimental Teratology of the Ministry of Education at Shandong University. Dr. Ma has interests in immune regulation and gene regulation in liver diseases. Dr. Ma’s expertise is in immune dysfunction in liver disease, hepatitis B and liver cancer.
Dr. Ma received her undergraduate from Shandong Normal University in 1991, and subsequently got her B.S degree from Huazhong Normal University in 1994 and her Ph.D degree in Immunology from Shandong University in 2002. In 1994, Dr. Ma joined department of microbiology and immunology, Shandong Medical University and went through the ranks of assistant professor and associate professor. From 2000, she works in Shandong University. Dr. Ma has extensive experience working with immune regulation and gene regulation in liver diseases. During her carrier in research, Dr. Ma gained awards from different society, including Young Teacher Award in the Higher Education Institutions of China, Fok Ying-Tong Education Foundation at 2003, New Century Excellent Talents in University of Ministry of Education of China at 2010, National Science Fund for Distinguished Young Scholars at 2014 and National high-level talents special support plan (Ten Thousand Talent Program) at 2016.
Dr. Hongping Xia received his M.D. degree from Wannan Medical College in 2004 and Ph.D. degree from the University of Hong Kong in 2011. He has been a Visiting Scholar in the Medical University of Vienna and a Clinician Scientist of Yijishan Hospital of Wannan Medical College. He is currently a Professor of Nanjing Medical University and a Research Fellow of National Cancer Center Singapore.
Molecular pathology & translational medicine
Principal Investigator of several national grants, such as The National Natural Science Foundation of China (NSFC, China) and National Medical Research Council (NMRC, Singapore). His studies have been published in the leading international journals including Hepatology, Journal of Hepatology, Gut, ACS Nano, and J Biol Chem, etc.
Dr Tornesello Maria Lina is Head of Viral and Tumour Marker Section in the Molecular Biology and Viral Oncology Laboratory at the National Cancer Institute Fond Pascale in Napoli – Italy. She graduated in Biological Science from the University of Naples Federico II in 1988 and received the specialty degree in Microbiology and Virology from the School of Medicine, at the University of Naples Federico II in 1994. She is involved in the study of the cooperation of oncogenic viruses and other cofactors including host susceptibility and accumulation of genetic alterations in the carcinogenesis of virus-driven tumors.
Pathogenesis of hepatitis related liver cancer
Stephen J. Beebe, molecular cell biologist / biochemist received his PhD in 1982 from the Medical College of Ohio, (now the Medical School at University of Toledo) in Medical Sciences (Pharmacology/ Biochemistry). He was a post-doctoral fellow at the Howard Hughes Medical Institute and Department of Molecular Physiology and Biophysics at Vanderbilt University, Nashville Tennessee. He was Fulbright Scholar at the University of Oslo, Norway and at the National Hospital and Department of Medical Biochemistry before taking a position as Assistant Professor in the Jones Institute for Reproductive Medicine and then an Associate Professor in the Department of Physiological Science and the Center for Pediatric Research at Eastern Virginia Medical School in Norfolk, Virginia. He is now a Professor at Old Dominion University in the Frank Reidy Research Center for Bioelectrics in Norfolk Virginia.
Physiological sciences; pediatric
1. Embryonic stem cells
2. Liver regeneration
3. Liver transplantation.
4. Liver stem cells
Dr. Di Fazio graduated as Biologist at University of Palermo in 2004. He worked as Research Fellow at Department of Pathology & Experimental and Clinical Medicine at University of Udine (2004/2005). He achieved his doctorate in Experimental Oncobiology (2007) at Department of Biochemical Sciences at University of Palermo where he started his PostDoc career. He was awarded of a fellowship from University of Palermo and a Short Term Fellowship from EASL. He moved to University of Marburg (2009) being awarded with a Sheila Sherlock PostDoc Fellowship from the European Association for the Study of the Liver (EASL). Since 2011, he is a permanent scientist at Marburg University at the Department of Visceral Thoracic and Vascular Surgery studying liver, thyroid and pancreas pathogenesis, apoptosis, ER stress and autophagy.
Liver fibrosis; cirrhosis and cancer; canonical and alternative mechanisms of cell death (ER stress, autophagy) and miRNAs activity in tumors
Dr. Pinar Erkekoglu is graduated from Hacettepe University Faculty of Pharmacy (BS) and Anadolu University Public Relations School (BS). She completed a part her PhD studies in Grenoble, France in Universite Joseph Fourier and CEA/INAC/LAN after receiving full scholarship from both European Union Erasmus Scholarship Program and from CEA. She worked as a post-doc and visiting associate in MIT (Massachusetts Institute of Technology) Biological Engineering Department between 2011 and 2012. Her main interests are the reproductive disorders, and oxidative stress induced by endocrine disrupting chemicals, particularly by phthalates, the protective role of selenium against oxidative stress and the toxic effects of aromatic amines. She has published more than 90 papers in national and international peer-reviewed journals and is currently working as an associate professor in Hacettepe University Faculty of Pharmacy Department of Pharmaceutical Toxicology. She is a European Registered Toxicologist (ERT) since 2014
Toxicology studies; male reproductive disorders
Samuel French is a liver pathologist and scientist who has been on faculty at the UCLA Department of Pathology since 2002. Dr. French earned his B.A. in Biophysics at U.C. Berkeley and M.D. and Ph.D. in Biochemistry at the University of Pittsburgh. He completed his residency in Pathology at UCLA as well as fellowship in gastrointestinal/liver pathology. He was a postdoctoral fellow at ucla where he worked on lymphomagenesis. He is a recipien of the Boyer-Parvin Postdoctoral Recognition Award and Cure Named New Investigator Award. Dr. French is currently developing a proteomic based program to study the developoment of liver cancer from hepatitis C viral infection.
Anatomic pathology; surgical pathology
Medical professor Yong-Song Guan is male, advisor of medical masters, mentor of medical doctorate and post-doctoral students. He is now a teacher in Sichuan University, an expert physician in Department of Oncology and Radiology of West China Hospital, and a post-retention member of State Key Laboratory of Biotherapy. He has been invited to serve as a member of the editorial board or reviewers of more than a dozen of medical journals home and abroad (many of the journals are indexed by SCI or MEDLINE). He has started his interventional career since 1986, and gained his experience in interventional diagnosis and management of more than 40,000 cases. He is good at the diagnosis and treatment of various difficult and stubborn diseases. He has been granted currently several research projects and fundations. He has been awarded several prizes, including Science and Technology Progress, 4 by Sichuan province government, one by Sichuan hygiene hall, 2 by Chengdu municipal government, and 7 excellent publication prizes by the province and municipality.
Gastroenterology and Hepatology
3. 3D imaging, X-ray computer
5. cancer gene therapy
6. carcinogenesis models
7. Diagnostic imaging
8. interventional therapy
9. Medical problem solving
10. Molecular Imaging
Fu Yang is the Director of the Department of Medical Genetics, Second Military Medical University, Shanghai, China. He has received the Ph.D. degree in genetics. In particular, his researches have been focused on exploring the changes of noncoding RNA expression profiles and regulatory networks in the progress of hepatocellular carcinoma (HCC).
Professor Sen-Yung Hsieh earned his MD degree from the National Yang Ming University in 1983, and obtained his PhD in Molecular Virology and Pathology from University of Pennsylvania in 1991. He received his clinical training in internal medicine, and subsequent a specialty in hepatogastroenterology in Chang Gung Memorial Hospital, Linko, Taiwan.
He initially focused on the molecular virology and epidemiology of human hepatitis viruses. His team for the first time identified the zoonotic transmission of hepatitis E virus from swine to humans in 1998, which was later found in other wild and domestic animals as natural reservoirs for sporadic hepatitis E in Japan and western countries. Currently, Dr. Hsieh is interested in elucidation the molecular mechanisms involving in carcinogenesis of human hepatoma. By integration of both functional genomics and proteomics approaches, he has identified novel oncogenes, tumor suppressor genes, and pathways that play significant roles in oncogenesis of human hepatoma. His works have been published in J Virology, Nucleic Acid Res, PNAS, Cancer Research, Oncogene, Proteomics, J Proteome Res, Mol Cell Proteomics, J Hepatology, and Hepatology.
1. Gastroenterology and hepatobiliary diseases
2. Hepatitis and hepatoma
3. The molecular mechanisms of hepatocellular carcinogenesis using the molecular and cellular biology, genomics and proteomics approaches.
4. Molecular virology and epidemiology of human hepatitis viruses
5. Hepatocellular carcinoma: carcinogenesis mechanisms, diagnosis, and treatments Functional genomics for novel genes and pathways implicated in hepatocellular carcinogenesis
Toru Ishikawa, Ph D, M.D., General Manager of Gastroenterology, Saiseikai Niigata Daini Hospital from 2008 to now. From 1992 to 1993, Ishikawa was a Resident in the Niigata University Hospital, Niigata, Japan. From 1993 to 1994, Ishikawa was a Resident in the Sinrakuen Hospital, Niigata, Japan. From 1994 to 1995, Ishikawa was a medical Staff in the Saiseikai Niigata Daini Hospital, Niigata, Japan. From 1995 to 2002, Ishikawa was a Resident in the the Third Department of Internal Medicine in the Niigata University Hospital, Niigata, Japan. From 2002 to 2007, Ishikawa was a Head Doctor of Gastroenterology, Saiseikai Niigata Daini Hospital.
Hepatocellular carcinoma; portal hypertension; hepatitis
The Dr Kayaalp was graduated as a Doctor of Medicine in 1989 from Hacettepe University.
The Dr Kayaalp's surgical education included Ankara Numune Hospital, General Surgery Department and Yuksek Ihtisas Hospital Department of Gastrointestinal Surgery. He has been studying at Inonu University, Department of General Surgery since 2005. Liver surgery is one of my favorite topics. He has several national and international studies about liver surgery. He is a member of Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association, Turkish Society of Gastroenterology and IASGO (International Association of Surgeons Gastroenterologists and Oncologists).
General surgery; gastrointestinal surgery; gastrointestinal and hepato-biliary-pancreatic surgery
Genomics; proteomics and systems biology of HCC including biomarker discovery and validation; and personalized medicine
T. B. Ng obtained his Ph.D. degree from the Memorial University of Newfoundland in Canada. He pursued postdoctoral training at the University of California in San Francisco. He is currently a professor of biochemistry at the School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong, China. His research interests encompass biologically active proteins and peptides of animal, plant, fungal and bacterial origins; polysaccharide-peptide complexe; polysaccharides; melatonin and derivatives; and natural products. He has supervised a large number of postdoctoral fellows and graduate students.He has published over five hundred papers in international journals and a number of book chapters.Some of these papers are about leguminous lectins, antifungal proteins, ribosome inactivating proteins, protease inhibitors, and peroxidases. He serves as the editorial board memeber of several journals including International Journal of Peptides, Journal of Biochemistry and Molecular Biology in the Post Genomic Era,and Frontiers in Cellulose Biotechnology. He has reviewed research grant applications and manuscripts submitted to various journals for publications.
1. proteins and peptides of human, plant, bacterial and fungal origins with antifungal, antibacterial and antiviral activities such as defensins, cathelicidin and lactoferrin and their mechanisms of action; many novel proteins and peptides were discovered during the course of investigation
2. isolation and characterization of enzymes of human, plant, bacterial and fungal origins including proteases, laccases, ribonucleases, deoxyribonucleases, phytases, cellulases, superoxide dismutases, peroxidases and lysozyme
3. isolation and characterization of various bovine milk proteins;several novel proteins were discovered during the course of investigation
4. proteins and peptides with anticancer activity in tumor-bearing animals, antiproliferative activity toward cancer cells and immunomodulatory activity such as lectins, ribosome inactivating proteins, ribonucleases, protease inhibitors, defensins, and cathelicidin and their mechanisms of action
5. roles of the receptors of the hormones melatonin and leptin in the etiology of adolescent idiopathic scoliosis; biological activities of the pineal hormone melatonin and its biosynthetic relatives
6. pharmacological activities such as antioxidant, antidiabetic, anticancer, and steroidogenic activities of medicinal plants including American ginseng, Chinese ginseng, sanchi ginseng, Codonopsis pilosula, bitter gourd, Trichosanthes, yam, and Dendrobium, herbal formulas such as Erxian decoction and Tian Xian liquid, and medicinal mushrooms such as Ganoderma, Coriolus versicolor, and Cordyceps
Dr. Raza graduated from the Sind Med Coll, Univ of Karachi, Karachi, Pakistan in 1982. She works in Loma Linda, CA and 1 other location and specializes in Anatomic Pathology & Clinical Pathology and Cytopathology. Dr. Raza is affiliated with Loma Linda University Medical Center, Loma Linda University Medical East and Loma Linda University Surgical Hospital.
Anatomic pathology & clinical pathology;surgical pathology; cytopathology
Prof. Sergio Sartori was born on June 22, 1954, and graduated cum laude in 1979. He is specialist in Gastroenterology and in Clinical Pharmacology, is dealing with interventional ultrasonography from 1990, and from 2002 is Chief of the Section of Interventional Ultrasound, St. Anna Hospital, Ferrara, Italy. He is author of more than 246 scientific papers.
Interventional ultrasound; endoscopy
Dr. Shilpa Sharma is a faculty (Asst. Professor) of Pediatric Surgery at All India Institute of Medical Sciences, New Delhi. Her qualifications include MBBS - 1996, MS Gen Surgery -1999, MCh and DNB - Pediatric Surgery - 2004. She is involved in the surgical care of children since last 15 years with research interests in stem cells. She has also done PhD on stem cells from All India Institute of Medical Sciences, New Delhi in 2010. Her notable awards include Dr. Shoor Vir Singh Prize, UC Chakravorty Research Award, Shanti Talwar Fellowship, Swapan Datta Research Award, Purushotom Upadhyay Research Award for the best paper published in 2010, James Lister fellowship of the British Association of Pediatric Surgeons in 2012 and the WOFAPS scholarship from the World Federation of Association of Pediatric Surgeons 2014 under which she was a fellow at GOS Hospital for Children at London, UK. She has published 56 research papers and 80 book chapters, delivered more than 60 guest lectures and presented more than 110 papers at various national and international conferences. She has served as an Editorial Assistant for Journal of Indian Association of Pediatric Surgeons and is presently an Editorial Consultant for two International journals apart from being a reviewer of many peer reviewed journals. She has served as Secretary of the Delhi chapter of Indian Association of Pediatric Surgeons from 2011-2014 and is currently the Secretary of the Research Section of the Indian Association of Pediatric Surgeons since 2011.
Nicola Silvestris graduated cum laude in 1993 from the Catholic University of Rome School of Medicine, Rome, Italy. He received his Ph.D. degree in 1998. Since graduation, he has become involved in studies on translational research in solid tumors. In this area, he is recognized as a national and international expert, as indicated by the numerous participations in meetings and seminars as an invited speaker. From 2011 he has been involved in the elaboration of guidelines of exocrine pancreatic carcinoma for the Italian Association of Medical Oncology. Since 2015, he is a Founding Member of the Italian Group for Diagnosis and Treatment of Biliary Cancer (GICO). He has published more than 140 papers in peer-reviewed journals. He regularly serves as a reviewer for the most important gastroenterology journals and for funding agencies.
Translational research (predictive and prognostic markers in gastrointestinal malignancies); treatment of gastrointestinal malignancies; conduction of clinical trials
Dr. Tombesi was born on April 27, 1976, and graduated cum laude in 2001. She is specialist in Internal Medicine and is dealing with interventional ultrasonography from 2003. She is working in the Section of Interventional Ultrasound, St. Anna Hospital, Ferrara, Italy, from 2006, and is author of 62 scientific papers.
Dr. Georgios Tsoulfas received his medical degree from Brown University School of Medicine and completed his general surgery residency at the University of Iowa Hospitals and Clinics, as well as a transplant research fellowship at the Starzl Transplant Institute at the University of Pittsburgh. He then completed a two-year transplantation surgery fellowship at the Massachusetts General Hospital, Harvard Medical School and then joined the Division of Solid Organ Transplantation and Hepatobiliary Surgery at the University of Rochester Medical Center as an assistant professor of surgery. He has recently returned to Greece where he is an Assistant Professor of Surgery at the Aristoteleion University of Thessaloniki.The recipient of awards such as the Edward E. Mason award for excellence in patient care and education and a member of the American Society of Transplant Surgeons Bylaws Committee, he is a member of a number of professional organizations including the American Society of Transplant Surgeons, Association for Academic Surgery, International College of Surgeons, American College of Surgeons, International Liver Transplantation Society, American Medical Association, Society for Laparoscopic Surgeons and International HepaticoPancreaticoBilliary Association.
Solid organ transplantation and hepatobiliary surgery
Dr. Xie is the associate professor of Department of Preventive Medicine, Bethune Medical NCOs School, Shijiazhuang, China. Dr. Xie received his PhD degree in epidemiology and health statistics from Second Military Medical University, Shanghai, China. Dr. Xie has done much epidemiological survey and laboratory work to investigate the associations of HBV infection, host susceptibility, and their interactions with liver diseases after HBV infection. He has found several novel HCC-related HBV mutations and STAT3 polymorphisms, which would be potential predictive markers for HCC.
1. HBV genotype and mutation
2. Gene polymorphism
3. Biological statistics
Dr. Yamaguchi graduated from Shizuoka College of Pharmacy (B.S.) in 1971 and obtained Ph.D of Pharmaceutical Sciences in 1976. He was engaged as Research Associate and Assistant Professor in Shizuoka College of Pharmacy (1973-1987). As Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka(1987-1991). As Associated Professor in University of Shizuoka, Graduate School of Nutritional Sciences (1991-1993) and Professor in University of Shizuoka, Graduate School of Nutritional Sciences (1993 ~ 2007) in Japan. From 2007, Yamaguchi was invited as Visiting Professor, Emory University School of Medicine, Department of Medicine. He was appointed Editorial Board Member of many Journals including International Journal of Molecular Medicine, Molecular Medicine Reports, Journal of Osteoporosis, International Journal of Medicine and Medical Sciences, International Journal of Nutrition and Metabolism, Molecular and Cellular Biochemistry, Endocrinology Studies, Alternative Medicine Studies, Experimental and Therapeutic Medicine, and Stem Cell Discovery. Yamaguchi published over 500 English original papers, review articles and books.
Hematology and biomedical oncology
Dr. Yanmin Zhang is a full professor of School of Pharmacy, Health Science Center, Xi'an Jiaotong University of China, member of Chinese Pharmaceutical Association. Yanmin Zhang received his B.S. in chemistry and Ph.D. in pharmaceutical analysis. He began his independent career in 1999. He is currently the director of molecular pharmacology program and assistant research scientist in the Biodesign Institute of Arizona State University, USA. He has held more than 10 national projects, published more than 100 papers including Pharmacol Therapeut, JACS, Org Lett, Chem Commu, CDDs, Sci Rep, Can lett, JCMM , et al. and held 26 patents.
Tumor Cell Biology
Screening of targeted drug